157 related articles for article (PubMed ID: 8682469)
1. Serum levels of circulating intercellular adhesion molecule 1 in hepatocellular carcinoma.
Hamazaki K; Gochi A; Shimamura H; Kaihara A; Maruo Y; Doi Y; Orita K; Lygidakis NJ
Hepatogastroenterology; 1996; 43(7):229-34. PubMed ID: 8682469
[TBL] [Abstract][Full Text] [Related]
2. Circulating intercellular adhesion molecule-1 in chronic liver disease and hepatocellular carcinoma.
Huang YS; Wu JC; Chan CY; Chao Y; Chang FY; Lee SD
Zhonghua Yi Xue Za Zhi (Taipei); 1999 Aug; 62(8):487-95. PubMed ID: 10462824
[TBL] [Abstract][Full Text] [Related]
3. Circulating intercellular adhesion molecule-1 in patients with hepatocellular carcinoma before and after hepatic resection.
Taketomi A; Takenaka K; Matsumata T; Shimada M; Higashi H; Shirabe K; Itasaka H; Adachi E; Maeda T; Sugimachi K
Hepatogastroenterology; 1997; 44(14):477-83. PubMed ID: 9164522
[TBL] [Abstract][Full Text] [Related]
4. Intercellular adhesion molecule-1 release from human hepatocellular carcinoma.
Hyodo I; Jinno K; Tanimizu M; Doi T; Nishikawa Y; Hosokawa Y; Moriwaki S
Cancer Detect Prev; 1996; 20(4):308-15. PubMed ID: 8818391
[TBL] [Abstract][Full Text] [Related]
5. Serum concentration of intercellular adhesion molecule-1 in patients with hepatocellular carcinoma is a marker of the disease progression and prognosis.
Shimizu Y; Minemura M; Tsukishiro T; Kashii Y; Miyamoto M; Nishimori H; Higuchi K; Watanabe A
Hepatology; 1995 Aug; 22(2):525-31. PubMed ID: 7543436
[TBL] [Abstract][Full Text] [Related]
6. Elevation of serum type IV collagen in liver cancer as well as liver cirrhosis.
Hong WS; Hong SI; Park SY; Son Y; Lee YS; Chung YH; Yang SK; Suh DJ; Min YI
Anticancer Res; 1995; 15(6B):2777-80. PubMed ID: 8669863
[TBL] [Abstract][Full Text] [Related]
7. Detection of circulating intercellular adhesion molecule-1 in hepatocellular carcinoma.
Hyodo I; Jinno K; Tanimizu M; Hosokawa Y; Nishikawa Y; Akiyama M; Mandai K; Moriwaki S
Int J Cancer; 1993 Nov; 55(5):775-9. PubMed ID: 7503959
[TBL] [Abstract][Full Text] [Related]
8. Des-gamma-carboxyprothrombin, alpha-fetoprotein and AFP-L3 in patients with chronic hepatitis, cirrhosis and hepatocellular carcinoma.
Durazo FA; Blatt LM; Corey WG; Lin JH; Han S; Saab S; Busuttil RW; Tong MJ
J Gastroenterol Hepatol; 2008 Oct; 23(10):1541-8. PubMed ID: 18422961
[TBL] [Abstract][Full Text] [Related]
9. Elevated plasma levels of matrix metalloproteinase-9 (92-kd type IV collagenase/gelatinase B) in hepatocellular carcinoma.
Hayasaka A; Suzuki N; Fujimoto N; Iwama S; Fukuyama E; Kanda Y; Saisho H
Hepatology; 1996 Nov; 24(5):1058-62. PubMed ID: 8903375
[TBL] [Abstract][Full Text] [Related]
10. Serum hepatocyte growth factor before and after resection for hepatocellular carcinoma.
Hu RH; Lee PH; Yu SC; Sheu JC; Lai MY
Hepatogastroenterology; 1999; 46(27):1842-7. PubMed ID: 10430357
[TBL] [Abstract][Full Text] [Related]
11. Serum des-gamma-carboxyprothrombin level by a modified enzyme immunoassay method in hepatocellular carcinoma: clinical significance in small hepatocellular carcinoma.
Soga K; Watanabe T; Aikawa K; Toshima M; Shibasaki K; Aoyagi Y
Hepatogastroenterology; 1998; 45(23):1737-41. PubMed ID: 9840138
[TBL] [Abstract][Full Text] [Related]
12. Thyroxine-binding globulin in patients with chronic hepatitis B virus infection: different implications in hepatitis and hepatocellular carcinoma.
Huang MJ; Liaw YF
Am J Gastroenterol; 1990 Mar; 85(3):281-4. PubMed ID: 1689951
[TBL] [Abstract][Full Text] [Related]
13. High serum vascular endothelial growth factor levels predict poor prognosis after radiofrequency ablation of hepatocellular carcinoma: importance of tumor biomarker in ablative therapies.
Poon RT; Lau C; Pang R; Ng KK; Yuen J; Fan ST
Ann Surg Oncol; 2007 Jun; 14(6):1835-45. PubMed ID: 17406950
[TBL] [Abstract][Full Text] [Related]
14. [Study on the prognostic value of hepatocyte growth factor and c-met for patients with hepatocellular carcinoma].
Wu FS; Zheng SS; Wu LJ; Ding W; Ma ZM; Wang ZM; Teng LS; Zhao WH
Zhonghua Wai Ke Za Zhi; 2006 May; 44(9):603-8. PubMed ID: 16784653
[TBL] [Abstract][Full Text] [Related]
15. Prognostic significance of three hepatitis markers (p53 antibodies, vascular endothelial growth factors and alpha fetoprotein) in patients with hepatocellular carcinoma.
Gadelhak NA; Gadelhak SA; El-Morsi DA; Abdelaziz MM; Abbas AT; El-Emshaty HM
Hepatogastroenterology; 2009; 56(94-95):1417-24. PubMed ID: 19950803
[TBL] [Abstract][Full Text] [Related]
16. Circulating platelet-derived endothelial cell growth factor increases in hepatocellular carcinoma patients.
Jin-no K; Tanimizu M; Hyodo I; Nishikawa Y; Hosokawa Y; Endo H; Doi T; Mandai K; Ishitsuka H
Cancer; 1998 Apr; 82(7):1260-7. PubMed ID: 9529017
[TBL] [Abstract][Full Text] [Related]
17. Increased level of serum hepatocyte growth factor/scatter factor in liver cancer is associated with tumor metastasis.
Junbo H; Li Q; Zaide W; Yunde H
In Vivo; 1999; 13(2):177-80. PubMed ID: 10363175
[TBL] [Abstract][Full Text] [Related]
18. Transforming growth factor beta1 and soluble Fas serum levels in hepatocellular carcinoma.
Sacco R; Leuci D; Tortorella C; Fiore G; Marinosci F; Schiraldi O; Antonaci S
Cytokine; 2000 Jun; 12(6):811-4. PubMed ID: 10843770
[TBL] [Abstract][Full Text] [Related]
19. Identification of cystatin B as a potential serum marker in hepatocellular carcinoma.
Lee MJ; Yu GR; Park SH; Cho BH; Ahn JS; Park HJ; Song EY; Kim DG
Clin Cancer Res; 2008 Feb; 14(4):1080-9. PubMed ID: 18281540
[TBL] [Abstract][Full Text] [Related]
20. Measurement of human intercellular adhesion molecule 1 in the blood is useful for predicting the occurrence of hepatocellular carcinomas from chronic hepatitis C and liver cirrhosis.
Moriyama M; Matsumura H; Shioda J; Aoki H; Nakamura H; Arakawa Y; Nirei K; Yamagami H; Kaneko M; Tanaka N; Arakawa Y
Intervirology; 2006; 49(6):327-38. PubMed ID: 16926545
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
